Safety study of NaPPS in pediatric patients with mucopolysaccharidosis type VI

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080223060

Enrollment

Registered

2016-01-04

Start date

2016-01-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

mucopolysaccharidosis type VI

Interventions

investigational material(s) Generic name etc : NaPPS INN of investigational material : Therapeutic category code : 399 Agents affecting metabolism, n.e.c. Dosage and Administration for Investigationa

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Patients who are confirmly diagnosed with Mucopolysaccharidosis type VI and have assessable symptoms of cartilage and bone. (2) Patients who are able to explain their own condition or to show their own intention. (3) Patients who are able to walk for 6 minutes continuously.

Exclusion criteria

Exclusion criteria:

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026